A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers
A Randomised, Double-blind, Placebo-controlled, Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of MT-2990 in Healthy Male Subjects
Sponsor: Tanabe Pharma Corporation
This PHASE1 trial investigates Healthy and is currently completed. Tanabe Pharma Corporation leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Jan 2026 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Nov 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2017 — Nov 2017 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Jul 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tanabe Pharma Corporation
For direct contact, visit the study record on ClinicalTrials.gov .